Effectiveness and Tolerability of First-Line Afatinib for Advanced EGFR-Mutant Non-Small Cell Lung Cancer in Vietnam.
Thanh Ha VuHoa Thi Thai NguyenLinh Khanh DaoChi Khanh DuongCao Van NguyenTuyet Thi DoanHang Thi Thuy NguyenHung Huy HoangDung Khac DinhGiang Vinh LeThanh Thi VuMinh Cong TruongLong Thanh NguyenPublished in: Asian Pacific journal of cancer prevention : APJCP (2021)
First-line afatinib is beneficial for Vietnamese patients with advanced EGFR-mutant NSCLC with a good response rate and prolonged TTF with manageable adverse event profile. Baseline brain metastasis status and starting doses do not significantly impact TTF.<br />.